Nektar Therapeutics
Robert Chess (Director) reports NKTR insider transactions
About this filing
Nektar Therapeutics (NKTR) filed Form 4 (insider transaction) with the SEC on Sep 25, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Robert Chess · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | A · grantFootnotes F1, F2, F3 | +2,000 | $0.00 | $0.00 | 19,019 | Direct |
| Sep 23, 2026 | A · grantStock OptionFootnotes F5 | +4,000 | $0.00 | $0.00 | 4,000 | Direct |
Footnotes
- F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
- F2 This RSU award vests in full, one year following September 23, 2026.
- F3 On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
- F4 The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
- F5 This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
More NKTR filings
- S-8
Filed Oct 19, 2026
- 8-K
Filed Oct 1, 2026
- SC 13G/A
Filed Sep 28, 2026
- 4
Filed Sep 25, 2026
- 4
Filed Sep 25, 2026
- 4
Filed Sep 25, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.